Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems |
| |
| Authors: | Anish Babu Anupama Munshi |
| |
| Affiliation: | 1. Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA;2. Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA;3. Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA;4. Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA |
| |
| Abstract: | RNA interference (RNAi) is emerging as a powerful approach in cancer treatment. siRNA is an important RNAi tool that can be designed to specifically silence the expression of genes involved in drug resistance and chemotherapeutic inactivity. Combining siRNA and other therapeutic agents can overcome the multidrug resistance (MDR) phenomenon by simultaneously silencing genes and enhancing chemotherapeutic activity. Moreover, the therapeutic efficiency of anticancer drugs can be significantly improved by additive or synergistic effects induced by siRNA and combined therapies. Co-delivery of these diverse anticancer agents, however, requires specially designed nanocarriers. This review highlights the recent trends in siRNA/anticancer drug co-delivery systems under the major categories of liposomes/lipid, polymeric and inorganic nanoplatforms. The objective is to discuss the strategies for nanocarrier-based co-delivery systems using siRNA/anticancer drug combinations, emphasizing various siRNA targets that help overcome MDR and enhance therapeutic efficiency. |
| |
| Keywords: | Cancer therapy chemotherapeutic co-delivery liposome nanoparticle siRNA |
|
|
